



To Study Lipid Profile Status in Chronic Obstructive Pulmonary Disease Patients.

Reena Jain¹, Pankaj Jain², Rachit Saxena³

^{1,3} MD Biochemistry, ² MD Pathology

^{1,2} Senior Demonstrator, ³ Assistant Professor

^{1,3} Government Medical College, Bhilwara.

² JLN medical College, Ajmer

Correspondence Author: Rachit Saxena, Assistant Professor, Government Medical College, Bhilwara.

Type of Publication: Original Research Paper

Conflicts of Interest: Nil

Abstract

Background-According to the statistics, chronic obstructive pulmonary disease (COPD) accounts for almost three million (5%) deceases worldwide in 2015. This disease is likely to increase in the coming years due to the growing prevalence of smoking and population aging in many countries.

Methods- This cross-sectional study was conducted on the inpatients and outpatients attending the Department of Respiratory. Therefore, a total of 30 COPD patients and including 30 control were enrolled in the study.

Results- The lipid profile in COPD patients, unpaired t test was performed and it was observed that COPD patients showed significantly higher serum levels of TC, TG, LDL and serum concentrations of HDL were also decreased significantly compared to controls.

Conclusion - COPD patients showed significantly higher serum levels of TC, TG, LDL and serum concentrations of HDL were also decreased significantly compared to controls.

Keywords: Lipid profile, chronic obstructive pulmonary disease, patients.

Introduction

According to the statistics, chronic obstructive pulmonary disease (COPD) accounts for almost three million (5%) deceases worldwide in 2015. This disease is likely to increase in the coming years due to the growing prevalence of smoking and population aging in many countries.¹ Metabolic syndrome which includes central obesity, diabetes, hypertension, and hyperlipidaemia, is known entity in COPD patients². Metabolic syndrome was associated with markers of systemic inflammation like Interleukin-6, C reactive protein, and fibrinogen etc³. There are limited number of studies investigating dyslipidemia in the COPD patients.

These studies have generally relied on questionnaires or diagnostic codes to determine the frequency of dyslipidemia in the patients with COPD, and it is unknown if dyslipidemia is another independent factor that could explain the increased risk of cardiovascular morbidity and mortality in the COPD patients⁴. The COPD patients are expected to have a deranged lipid profile for various reasons like smoking, aging, and using such drugs as steroids.

Materials and Methods

This cross-sectional study was conducted on the inpatients and outpatients attending the Department of Respiratory. Therefore, a total of 30 COPD patients and including 30 controls were enrolled in the study.

The exclusion criteria included

- 1) Uncooperativeness and unwillingness to participate in the study,
- 2) Being seriously ill,
- 3) Known case of carcinoma, bronchial asthma, active tuberculosis, diabetes, hypertension, collagen vascular disease,
- 4) Inability to properly perform spirometry,
- 5) The presence of congenital or valvular cardiomyopathy or other familial hyperlipidemias. After the informed consent was obtained from all the participants. Subsequently, the COPD patients were segregated and diagnosed based on the GOLD guidelines with such risk factors as dyspnea, chronic cough, chronic sputum production, history of exposure to the respective risk factors, and age of > 40 years. a detailed history was obtained from all the patients; furthermore, clinical examination and radiological tests were performed to confirm the presence of COPD and the associated cardiovascular complications.

After a 12-hour overnight fast, 5 ml fasting blood samples were collected from all the participants in the morning. The total cholesterol, HDL, and triglycerides were directly analyzed using the standard enzymatic techniques.

Results

Mean age in COPD patients was 35.20 ± 11.50 years and control patients was 38.20 ± 8.74 years and age range was 20-60 years. Both groups were well matched for age and sex distribution.

Table .1. Comparision of biochemical parameters in case and controls.

Parameters	Case (n=30)	Control (n=30)	p-value
Mean Total cholesterol	186.20 ± 22.40	173.20 ± 15.20	<0.05
Mean LDL	118.50 ± 12.80	110.80 ± 11.50	<0.05
Mean HDL	33.40 ± 4.20	37.90 ± 5.20	<0.05
Mean Triglycerides	148.50 ± 12.50	134.20 ± 11.80	<0.05

The lipid profile in COPD patients, unpaired t test was performed and it was observed that COPD patients showed significantly higher serum levels of TC, TG, LDL and serum concentrations of HDL were also decreased significantly compared to controls.

Discussion

COPD is associated with significantly increased morbidity and mortality and COPD precipitates dyslipidemia. So present was conducted and found that COPD patients showed significantly higher serum levels of TC, TG, LDL and serum concentrations of HDL were decreased significantly. This finding was corroborated with the results of some previous studies ^{4,5}.

Although Kamat SR, et al. In their study has shown the serum of lipid parameters are not different in COPD from healthy controls⁶. Smoking can cause major changes in serum lipid profile simultaneously smoking is a major risk factor in COPD. Smoking affects the lipid profile such a way that the plasma LDL, cholesterol and triglycerides concentration are higher and HDL cholesterol is lower in smoker than in nonsmokers⁷.

Nicotine causes the release of adrenaline from the adrenal cortex leading to increased serum concentration of free fatty acids (FFA) which stimulates hepatic synthesis and secretion of cholesterol as well as hepatic secretion of VLDL and hence increased TG. Smoking decreases estrogen levels and further leads to decreased HDL cholesterol concentration. Smoking also increases insulin resistance and LDL, VLDL and TG are elevated in this

hyperinsulinemic conditions due to decreased activity of lipoprotein lipase⁸.

Conclusion

COPD patients showed significantly higher serum levels of TC, TG, LDL and serum concentrations of HDL were also decreased significantly compared to controls.

References

1. Senior RM, Anthonisen NR. Chronic obstructive pulmonary disease (COPD). *Am J Respir Crit Care Med*. 1998; 157:S139-47.
2. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. *PLoS Med*. 2010; 7:1-4.
3. Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. *Chest*. 2009; 136:1039-46.
4. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2008; 4:549-55.
5. Begum K, Begum MK, Sarker ZH, Dewan MRK, Siddique MJH. Lipid profile status of chronic obstructive pulmonary disease in hospitalized patients. *Bangladesh J Med Biochem*. 2010;3(2):42-45.
6. Nillawar AN, Joshi KB, Patil SB, Bardapurkar JS, Bardapurkar SJ. Evaluation of HS-CRP and Lipid Profile in COPD. *J Clin Diagn Res*. 2013;7:801-3.
7. Ebrahimi M, Kazemi-Bajestani SM, Ghayour-Mobarhan M, Moohebbati M, Paydar R, Azimi-Nezhad M, et al. Metabolic syndrome may not be a good predictor of coronary artery disease in the Iranian population: Population-specific definitions are required. *Scientific World Journal*. 2009;9:86-96.
8. Rao MV, Raghu S, Kiran S, Rao CH. A study of lipid profile in chronic obstructive pulmonary disease. *J of*

Evolution of Med and Dent Sci. 2015;4(42):7286-7295. DOI: 10.14260/jemds/2015/1059.